Rapid Communications

Diabetologia

, Volume 34, Issue 2, pp 129-132

First online:

Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patients

  • T. SankeAffiliated withThe First Department of Medicine, Wakayama University of Medical Science
  • , T. HanabusaAffiliated withThe First Department of Medicine, Wakayama University of Medical Science
  • , Y. NakanoAffiliated withThe First Department of Medicine, Wakayama University of Medical Science
  • , C. OkiAffiliated withThe First Department of Medicine, Wakayama University of Medical Science
  • , K. OkaiAffiliated withThe First Department of Medicine, Wakayama University of Medical Science
  • , S. NishimuraAffiliated withThe First Department of Medicine, Wakayama University of Medical Science
  • , M. KondoAffiliated withThe First Department of Medicine, Wakayama University of Medical Science
  • , K. NanjoAffiliated withThe First Department of Medicine, Wakayama University of Medical Science

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Fasting plasma islet amyloid polypeptide concentrations and their responses to an oral glucose load were determined in non-diabetic control subjects and patients with abnormal glucose tolerance in relation to the responses of insulin or C-peptide. Plasma islet amyloid polypeptide was measured by radioimmunoassay. In the non-diabetic control subjects, fasting plasma islet amyloid polypeptide was 6.4±0.5 fmol/ml (mean ± SEM) and was about 1/7 less in molar basis than in insulin. The fasting islet amyloid polypeptide level rose in obese patients and fell in patients with Type 1 (insulin-dependent) diabetes mellitus. In non-obese patients with impaired glucose tolerance and Type 2 (non-insulin-dependent) diabetic patients without insulin therapy, the level was equal to that of the control subjects, but a low concentration of islet amyloid polypeptide relative to insulin or C-peptide was observed in the non-obese Type 2 diabetic group. The patterns of plasma islet amyloid polypeptide responses after oral glucose were similar to those of insulin or C-peptide. However, compared to non-obese patients, a hyper-response of islet amyloid polypeptide relative to C-peptide was noted in obese patients who had a hyper-response of insulin relative to C-peptide. This study suggests that basal hypo-secretion of islet amyloid polypeptide relative to insulin exists in non-obese Type 2 diabetes and that circulating islet amyloid polypeptide may act physiologically with insulin to modulate the glucose metabolism.

Key words

Islet amyloid polypeptide amylin diabetes mellitus fasting concentration oral glucose tolerance test